Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella Theory

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04525807

Enrollment

200

Registered

2020-08-25

Start date

2020-09-01

Completion date

2022-09-01

Last updated

2020-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer Metastatic

Brief summary

In order to more accurately discover the cause of drug resistance in tumor treatment, and to provide a new basis for precise treatment. Therefore, based on the umbrella theory of precision medicine, we carried out this single-center, prospective, and observational study to include patients with liver metastases from colorectal cancer. By combining genome, transcriptome, and proteomic sequencing data, we established a basis for colorectal cancer liver Transfer the multi-omics data of the sample, describe the reason for the resistance of the first-line treatment, and search for new therapeutic targets.

Interventions

DIAGNOSTIC_TESTMulti-omics

Use multi-omics to analyze

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* ECOG score 0-2 points * Pathologically diagnosed patients with colorectal cancer * Combined with liver metastases confirmed by imaging, and the lesion is measurable (RECIST standard) * The lesion is available * First-line treatment failed; hematology, liver and kidney function tests are suitable for back-line treatment * Informed consent

Exclusion criteria

* With brain metastases * History of other malignancies * Pregnancy or breastfeeding * Have received other drug clinical studies within 30 days before the start of this study

Design outcomes

Primary

Measure	Time frame	Description
Objective response rate	1 year	Refers to the proportion of patients whose tumors have shrunk to a certain amount and maintained for a certain period of time, including complete remission (CR) and partial remission (PR) cases

Secondary

Measure	Time frame	Description
progression-free survival	1 year	Refers to the date from initial diagnosis to tumor progression
Overall survival	3 years	Refers to the date from initial diagnosis to last follow-up or death date

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026